Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR
ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.
ANGLE plc ha presentato nuovi dati alla Conferenza Speciale AACR che mostrano il loro assay PD-L1 basato su Parsortix per il monitoraggio del cancro ai polmoni. L'assay ha dimostrato un'elevata sensibilità analitica e specificità nell'identificazione di diversi fenotipi CTC e nella determinazione dello stato di PD-L1. In uno studio su pazienti con cancro ai polmoni metastatico, i CTC sono stati identificati nel 91% dei casi, con CTC PD-L1 positivi trovati nel 72% dei pazienti con biopsie tissutali positive per PD-L1 e nel 27% di coloro con biopsie negative. La tecnologia consente un monitoraggio longitudinale minimamente invasivo dello stato di PD-L1, potenzialmente migliorando gli approcci terapeutici personalizzati.
ANGLE plc ha presentado nuevos datos en la Conferencia Especial de la AACR que muestran su ensayo de PD-L1 basado en Parsortix para el monitoreo del cáncer de pulmón. El ensayo demostró una alta sensibilidad analítica y especificidad en la identificación de diferentes fenotipos de CTC y en la determinación del estado de PD-L1. En un estudio de pacientes con cáncer de pulmón metastásico, se identificaron CTC en el 91% de los casos, con CTC positivos para PD-L1 encontrados en el 72% de los pacientes con biopsias de tejido positivas para PD-L1 y en el 27% de aquellos con biopsias negativas. La tecnología permite un monitoreo longitudinal mínimamente invasivo del estado de PD-L1, avanzando potencialmente en los enfoques de tratamiento personalizado.
ANGLE plc는 폐암 모니터링을 위한 Parsortix 기반 PD-L1 검사의 새로운 데이터를 AACR 특별 회의에서 소개했습니다. 이 검사는 다양한 CTC 표현형을 식별하고 PD-L1 상태를 결정하는 데 있어 높은 분석적 민감도와 특이성을 보여주었습니다. 전이성 폐암 환자에 대한 연구에서 CTC는 91%의 경우에서 확인되었으며, PD-L1 양성 조직 생검을 가진 환자 중 72%에서 PD-L1 양성 CTC가 발견되었고, 음성 생검을 가진 환자 중에서는 27%에서 발견되었습니다. 이 기술은 PD-L1 상태의 최소 침습적이고 장기적인 모니터링을 가능하게 하여 개인 맞춤형 치료 접근 방식을 발전시킬 수 있습니다.
ANGLE plc a présenté de nouvelles données lors de la Conférence Spéciale AACR présentant leur essai PD-L1 basé sur Parsortix pour le suivi du cancer du poumon. L'essai a montré une grande sensibilité analytique et spécificité pour identifier différents phénotypes de CTC et déterminer l'état de PD-L1. Dans une étude sur des patients atteints de cancer du poumon métastatique, les CTC ont été identifiés dans 91% des cas, avec des CTC PD-L1 positifs trouvés dans 72% des patients ayant des biopsies tissulaires positives pour PD-L1 et 27% de ceux ayant des biopsies négatives. La technologie permet un suivi longitudinal minimement invasif de l'état de PD-L1, ce qui pourrait faire progresser les approches de traitement personnalisé.
ANGLE plc hat auf der AACR-Sonderkonferenz neue Daten präsentiert, die ihr auf Parsortix basierendes PD-L1-Assay zur Überwachung von Lungenkrebs vorstellen. Das Assay zeigte eine hohe analytische Sensitivität und Spezifität bei der Identifizierung verschiedener CTC-Phänotypen und der Bestimmung des PD-L1-Status. In einer Studie über Patienten mit metastasiertem Lungenkrebs wurden CTCs in 91% der Fälle identifiziert, wobei PD-L1-positive CTCs bei 72% der Patienten mit PD-L1-positiven Gewebebiopsien und bei 27% derjenigen mit negativen Biopsien gefunden wurden. Die Technologie ermöglicht ein minimal invasives, langfristiges Monitoring des PD-L1-Status, was potenziell personalisierte Behandlungsansätze vorantreibt.
- High detection rate with CTCs identified in 91% of metastatic lung cancer patients
- Successful analytical verification with high sensitivity and specificity
- Technology enables minimally invasive monitoring compared to traditional tissue biopsies
- None.
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment
GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research, Liquid Biopsy: From Discovery to Clinical Implementation, in San Diego, US from 13 to 16 November 2024.
ANGLE is presenting a poster entitled "Investigating PD-L1 status in circulating tumor cells isolated from the blood samples of lung cancer patients". The poster presentation reports on ANGLE's immunofluorescence assay for the identification of different CTC phenotypes (epithelial, mesenchymal and those transitioning) and the determination of Programmed Death Ligand-1 (PD-L1) status. Analytical verification demonstrated that the assay successfully produced linear data with high analytical sensitivity1 and specificity2 for epithelial, mesenchymal, blood lineage and PD-L1 markers.
PD-L1 allows cancer cells to evade the host immune response when upregulated, and assessment of PD-L1 status in tumour tissue can indicate if immunotherapy has the potential to be an effective treatment. However, lung tissue biopsies can be challenging and expensive and are not always successful, plus PD-L1 status in tumour tissue can become outdated during tumour evolution and may not be representative of metastatic sites. ANGLE has developed a liquid biopsy assay that allows for minimally invasive, longitudinal monitoring of PD-L1 status in CTCs harvested using the Parsortix® system.
The assay identified CTCs in
A patient case study revealed that CTC PD-L1 status varied between blood draws, showing discordance with the initial tumour biopsy at multiple time points. The results presented in this study demonstrate the potential for the development of CTC-based dynamic PD-L1 testing to advance personalised treatment for metastatic lung cancer patients.
Chief Scientific Officer, Karen Miller, commented:
"We are pleased to have presented this poster at the AACR Special Conference in Cancer Research. The results of this study further demonstrate the utility of ANGLE's PD-L1 assay. Longitudinal monitoring is essential to the advancement of personalised medicine, and we look forward to contributing to this advancement and supporting the needs of our pharma customers through development of our CTC-based assays."
The poster is available for review at: https://angleplc.com/resources/posters/
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Research Use Only. Not for use in diagnostic procedures.
1. Analytical sensitivity = proportion of harvested cells known to express the marker(s) of interest which were marker positive in the assay.
2. Analytical specificity = proportion of harvested cells known to NOT express the marker(s) of interest which were marker negative in the assay.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What are the success rates of ANGLE's (ANPCY) Parsortix PD-L1 assay in detecting CTCs in lung cancer patients?
What percentage of PD-L1 positive tissue biopsy patients showed positive CTCs using ANGLE's (ANPCY) assay?
How does ANGLE's (ANPCY) Parsortix system improve upon traditional tissue biopsies for lung cancer?
